84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]楊愛娟,徐保平,王曉濤.新風(fēng)膠囊治療強(qiáng)直性脊柱炎臨床療效的系統(tǒng)評價[J].中醫(yī)正骨,2020,32(07):12-16.
　YANG Aijuan,XU Baoping,WANG Xiaotao.Clinical efficacy of Xinfeng(新風(fēng))capsule for treatment of ankylosing spondylitis:a systematic review[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2020,32(07):12-16.
點(diǎn)擊復(fù)制

新風(fēng)膠囊治療強(qiáng)直性脊柱炎臨床療效的系統(tǒng)評價()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第32卷
期數(shù):
2020年07期
頁碼:
12-16
欄目:
文獻(xiàn)研究
出版日期:
2020-07-20

文章信息/Info

Title:
Clinical efficacy of Xinfeng(新風(fēng))capsule for treatment of ankylosing spondylitis:a systematic review
作者:
楊愛娟1; 徐保平2; 王曉濤3
1.北京中醫(yī)藥大學(xué),北京 100029; 2.六安市中醫(yī)院,安徽 六安 237000; 3.無錫市錫山人民醫(yī)院鵝湖分院,江蘇 無錫 214116
Author(s):
YANG Aijuan1; XU Baoping2; WANG Xiaotao3
1.Beijing University of Chinese Medicine,Beijing 100029,China 2.Traditional Chinese Hospital of Lu'an,Lu'an 237000,Anhui,China 3.Ehu branch of Xishan People's Hospital of Wuxi City,Wuxi 214116,Jiangsu,China
關(guān)鍵詞:
脊柱炎; 強(qiáng)直性;  Meta分析;  柳氮磺胺吡啶;  新風(fēng)膠囊
Keywords:
spondylitis; ankylosing;  Meta-analysis;  sulfasalazine;  Xinfeng capsule
摘要:
目的:系統(tǒng)評價新風(fēng)膠囊治療強(qiáng)直性脊柱炎的臨床療效。方法:檢索Cochrane Library、CBM、CNKI、Pubmed、Web of Science、VIP、WanFang Data建庫至2019年8月收錄的新風(fēng)膠囊治療強(qiáng)直性脊柱炎的臨床研究文獻(xiàn)。中文檢索詞為“新風(fēng)膠囊”“強(qiáng)直性脊柱炎”; 英文檢索詞為“Xinfeng capsule”“ankylosing spondylitis”。由2名研究者獨(dú)立篩選文獻(xiàn)、提取文獻(xiàn)中的數(shù)據(jù)資料。對納入文獻(xiàn)進(jìn)行質(zhì)量評價后進(jìn)行Meta分析。結(jié)果:共檢索到101篇文獻(xiàn),經(jīng)篩選后最終納入10篇文獻(xiàn)。納入的10篇文獻(xiàn),9篇文獻(xiàn)說明了隨機(jī)方法,1篇僅提及“隨機(jī)”未說明具體方法; 均未提及分配隱藏和盲法; 結(jié)局?jǐn)?shù)據(jù)均未缺失; 6篇文獻(xiàn)無選擇性報告,其余4篇研究信息不全、難以判斷; 均無法判斷其他偏倚來源。Meta分析結(jié)果顯示,新風(fēng)膠囊治療強(qiáng)直性脊柱炎,治療后患者的Bath強(qiáng)直性脊柱炎活動性指數(shù)、Bath強(qiáng)直性脊柱炎功能指數(shù)、Bath強(qiáng)直性脊柱炎整體指數(shù)、疼痛視覺模擬量表評分均低于柳氮磺胺吡啶治療[I2=80%,MD=-0.86,95%CI(-1.21,-0.51); I2=45%,MD=-0.74,95%CI(-0.90,-0.59); I2=47%,MD=-0.88,95%CI(-1.04,-0.72); I2=82%,MD=-1.27,95%CI(-1.66,-0.88)]。結(jié)論:新風(fēng)膠囊治療強(qiáng)直性脊柱炎可有效緩解癥狀、提高患者生活質(zhì)量。
Abstract:
Objective:To systematically review the clinical efficacy of Xinfeng(新風(fēng),XF)capsule for treatment of ankylosing spondylitis(AS).Methods:All clinical trial articles about XF capsule for treatment of AS included from database establishing to August 2019 were retrieved from Cochrane Library,CBM,China national knowledge internet,Pubmed,Web of Science,VIP Database and WanFang Data through computer.The logical combination of“新風(fēng)膠囊”and“強(qiáng)直性脊柱炎”were used as Chinese index terms,and the logical combination of Xinfeng capsule and ankylosing spondylitis as the English index terms.The articles were screened and the information was extracted independently by two searchers.The methodological quality of research in the articles was evaluated and a Meta-analysis was conducted.Results:One hundred and one articles were searched out.After screening,10 articles were included in the final analysis,including 9 articles in which randomization method was described and 1 article in which only randomization was mentioned and randomization method was not described.Meanwhile,the reports were non-selective in 6 articles and were difficult to judge for incomplete information in the other four articles.Besides,the allocation concealment and blind method were not mentioned,and outcome data were complete in all of the 10 articles,and other sources of bias couldn't be identified.The results of Meta-analysis demonstrated that the posttreatment Bath ankylosing spondylitis disease active index(BASDAI),Bath ankylosing spondylitis functional index(BASFI),Bath ankylosing spondylitis global index(BAS-G)and pain visual analog scale(VAS)scores were lower in patients who received XF capsule compared to patients who received sulfasalazine for treatment of AS(I2=80%,MD=-0.86,95%CI(-1.21,-0.51); I2=45%,MD=-0.74,95%CI(-0.90,-0.59); I2=47%,MD=-0.88,95%CI(-1.04,-0.72); I2=82%,MD=-1.27,95%CI(-1.66,-0.88)).Conclusion:XF capsule can effectively relieve symptoms and improve patient's life quality in treatment of AS.

參考文獻(xiàn)/References:

[1] 葛均波,徐永健.內(nèi)科學(xué)[M].北京:人民衛(wèi)生出版社,2013:822-824.
[2] SCHOELS M M,BRAUN J,DOUGADOS M,et al.Treating axial and peripheral spondyloarthritis,including psoriatic arthritis,to target:results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis[J].Ann Rheum,2014,73(1):238-242.
[3] RAMOS-REMUS C,HERNANDEZ-RIOS G,DURAN-BARRAGAN S,et al.Fifteen-year trends of long-term disability and sick leaves in ankylosing spondylitis[J].Clin Rheumatol,2011,30(3):361-367.
[4] 邢帥,高延征,高坤,等.非甾體類抗炎藥治療強(qiáng)直性脊柱炎的研究現(xiàn)狀及展望[J].風(fēng)濕病與關(guān)節(jié)炎,2015,4(3):60-63.
[5] 馬麗瑤,李涯松.強(qiáng)直性脊柱炎骨量丟失的中西醫(yī)結(jié)合診治進(jìn)展[J].中國骨質(zhì)疏松雜志,2017,23(1):136-140.
[6] 縱瑞凱.新風(fēng)膠囊組方及其治療類風(fēng)濕關(guān)節(jié)炎的作用[J].風(fēng)濕病與關(guān)節(jié)炎,2013,2(1):47-49.
[7] 朱福兵,劉健,方利,等.新風(fēng)膠囊治療58例干燥綜合征療效觀察[J].中國中西醫(yī)結(jié)合雜志,2016,36(11):1323-1328.
[8] VAN DER LINDEN S,VALKENBURG H A,CATS A.Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria[J].Arthritis Rheum,1984,27(4):361-368.
[9] 鄭筱萸.中藥新藥臨床研究指導(dǎo)原則[J].北京:中國醫(yī)藥科技出版社,2002:119.
[10] ZENG X,ZHANG Y,KWONG J S,et al.The methodological quality assessment tools for preclinical and clinical studies,systematic review and meta-analysis,and clinical practice guideline:a systematic review[J].J Evid Based Med,2015,8(1):2-10.
[11] 諶曦,劉健,黃傳兵.清熱補(bǔ)腎健脾通絡(luò)法合新風(fēng)膠囊治療活動期強(qiáng)直性脊柱炎25例[J].安徽中醫(yī)學(xué)院學(xué)報,2011,30(5):32-35.
[12] 汪四海,劉健,張金山,等.中醫(yī)健脾單元療法治療強(qiáng)直性脊柱炎臨床觀察[J].中醫(yī)藥臨床雜志,2011,23(5):401-404.
[13] 汪四海,劉健,楊佳,等.中醫(yī)健脾單元療法對強(qiáng)直性脊柱炎患者療效及BGP、TRACP的影響[J].世界中西醫(yī)結(jié)合雜志,2012,7(5):399-403.
[14] 劉健,盛長健,謝秀麗,等.益氣健脾中藥對強(qiáng)直性脊柱炎的療效及焦慮抑郁的影響[J].中醫(yī)藥臨床雜志,2010,22(9):792-795.
[15] LIU J,QI Y,ZHENG L,et al.Xinfeng capsule improves pulmonary function in ankylosing spondylitis patients via NF-ΚB-iNOS-NO signaling pathway[J].J Tradit Chin Med,2014,34(6):657-665.
[16] 王桂珍,劉健,曹云祥,等.新風(fēng)膠囊聯(lián)合中藥熏蒸治療強(qiáng)直性脊柱炎臨床觀察[J].中醫(yī)藥臨床雜志,2014,26(6):581-583.
[17] 齊亞軍,劉健,鄭力,等.新風(fēng)膠囊治療對強(qiáng)直性脊柱炎患者BTLA+T細(xì)胞數(shù)量和氧化應(yīng)激的影響[J].細(xì)胞與分子免疫學(xué)雜志,2014,30(10):1084-1089.
[18] 齊亞軍,劉健,鄭力,等.基于B、T淋巴細(xì)胞衰減因子及氧化應(yīng)激探討新風(fēng)膠囊治療強(qiáng)直性脊柱炎的作用機(jī)制[J].中國中西醫(yī)結(jié)合雜志,2015,35(1):25-32.
[19] 方利,劉健,朱福兵,等.新風(fēng)膠囊對強(qiáng)直性脊柱炎活動期患者血液高凝狀態(tài)影響及其機(jī)制探討[J].世界中西醫(yī)結(jié)合雜志,2016,11(7):949-955.
[20] 葉文芳,劉健,萬磊,等.新風(fēng)膠囊對強(qiáng)直性脊柱炎患者療效及血清免疫球蛋白亞型、外周血淋巴細(xì)胞自噬的影響[J].中國中西醫(yī)結(jié)合雜志,2016,36(3):310-316.
[21] 方利,劉健,萬磊,等.新風(fēng)膠囊通過抑制miR-155/NF-κB信號通路改善強(qiáng)直性脊柱炎活動期患者高凝狀態(tài)[J].細(xì)胞與分子免疫學(xué)雜志,2016,32(8):1094-1098.
[22] 方妍妍,劉健,萬磊,等.新風(fēng)膠囊含藥血清通過抑制VEGFA/SDF-1/CXCR4通路緩解強(qiáng)直性脊柱炎患者血小板活化的機(jī)制[J].免疫學(xué)雜志,2019,35(8):691-696.

相似文獻(xiàn)/References:

[1]閻曉霞,任之強(qiáng),仝允輝,等.布魯氏菌性脊柱炎3例[J].中醫(yī)正骨,2015,27(06):64.
[2]趙偉光,劉振武,劉利,等.強(qiáng)直性脊柱炎合并右側(cè)股骨頭和股骨頸骨溶解癥1例[J].中醫(yī)正骨,2015,27(01):75.
[3]黃建武,黃建華,黃影.腫瘤壞死因子-α在強(qiáng)直性脊柱炎活動期患者中的表達(dá)[J].中醫(yī)正骨,2013,25(11):22.
[4]張董喆,孔超,張建福.針刺夾脊穴結(jié)合督灸治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2014,26(07):58.
[5]吳建國.強(qiáng)直性脊柱炎并發(fā)脊柱骨折的影像學(xué)表現(xiàn)[J].中醫(yī)正骨,2013,25(06):31.
[6]謝國華,薛峰,楊建平,等.強(qiáng)直性脊柱炎脊柱應(yīng)力性骨折的診斷[J].中醫(yī)正骨,2012,24(12):72.
[7]張萬義,張永紅,王笑青.雙醋瑞因膠囊聯(lián)合柳氮磺胺吡啶腸溶片與右旋布洛芬膠囊治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2012,24(06):26.
　ZHANG Wan-yi*,ZHANG Yong-hong,WANG Xiao-qing.*.Study on the curative effects of diacerein capsules combined with sulfasalazine enteric-coated tablets and dextral ibuprofen capsules in the treatment of ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(07):26.
[8]黃建華,黃建武,陳金春,等.早期強(qiáng)直性脊柱炎血管內(nèi)皮生長因子、C反應(yīng)蛋白 表達(dá)水平的臨床研究[J].中醫(yī)正骨,2012,24(02):9.
　HUANG Jian-hua*,HUANG Jian-wu,CHEN Jin-chun,et al.Clinical research on the expression of VEGF、CRP in early ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(07):9.
[9]王笑青,張永紅,王玉麗,等.常規(guī)藥物口服配合中藥離子導(dǎo)入治療強(qiáng)直性脊柱炎肌腱附著點(diǎn)炎[J].中醫(yī)正骨,2011,23(10):18.
　WANG Xiao-qing*,ZHANG Yong-hong,WANG Yu-li,et al.A study on the curative effects of oral conventional drugs combined with traditional Chinese medicine iontophoresis on ankylosing spondylitis tendon enthesitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(07):18.
[10]劉紅軍.單節(jié)段楔形截骨結(jié)合椎弓根A-F系統(tǒng)內(nèi)固定 治療強(qiáng)直性脊柱炎脊柱后凸畸形[J].中醫(yī)正骨,2011,23(09):65.
[11]戴霞華,李寅潔.指導(dǎo)性功能鍛煉在兒童強(qiáng)直性脊柱炎護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2015,27(10):78.
[12]張夢雨,鮑鐵周,田江波.督脈隔姜灸聯(lián)合柳氮磺吡啶腸溶片口服及 功能鍛煉治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2015,27(09):44.
[13]赫軍,諸葛天諭,李冬冬,等.中藥內(nèi)服聯(lián)合針刺與埋針法治療幼年強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(01):41.
[14]赫軍,諸葛天諭,李冬冬,等.四聯(lián)療法治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(06):50.
[15]張遂連,袁星星.自我管理在強(qiáng)直性脊柱炎患者門診護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2017,29(03):79.
[16]李現(xiàn)林,薛華珍,陳星,等.口服通痹舒筋丸治療強(qiáng)直性脊柱炎寒濕痹阻證[J].中醫(yī)正骨,2017,29(05):31.
[17]龔家川.影響強(qiáng)直性脊柱炎患者髖關(guān)節(jié)受累的危險因素分析[J].中醫(yī)正骨,2017,29(06):25.
　GONG Jiachuan.Analysis of risk factors for affection of hip joint in patients with ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(07):25.
[18]黃小龍,全仁夫,胡華輝,等.HLA-B2704基因型強(qiáng)直性脊柱炎患者來源的人誘導(dǎo)多能干細(xì)胞體系的建立[J].中醫(yī)正骨,2017,29(12):11.
　HUANG Xiaolong,QUAN Renfu,HU Huahui,et al.Establishment of human-induced pluripotent stem cells system originated from patients with HLA-B2704 genotypic ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(07):11.
[19]李洛宜,張依山,王笑青,等.系列化視頻在強(qiáng)直性脊柱炎健康教育中的應(yīng)用[J].中醫(yī)正骨,2018,30(03):78.
[20]任偉凡,胡勁濤,全仁夫,等.強(qiáng)直性脊柱炎易感基因的相關(guān)研究進(jìn)展[J].中醫(yī)正骨,2019,31(04):48.

備注/Memo

備注/Memo:
通訊作者:王曉濤 E-mail:[email protected]
更新日期/Last Update: 2020-07-20